Advert - Swedish Orphan Biovitrum (Sobi)
Date posted12 March 2021
For failing to include accurate information about the side effects of Alprolix (eftrenonacog alfa) and not reflecting the available information, Sobi was ruled in breach of the following clauses of the Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 7.2 - Making a misleading claim
Clause 7.4 - Making an unsubstantiated claim
Clause 7.9 - Making claims that did not reflect the available evidence regarding possible adverse reactions
Clause 9.1 - Failing to maintain high standards.